Renal Doppler in Pediatric Patients With Idiopathic Nephrotic Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05912673 |
Recruitment Status :
Completed
First Posted : June 22, 2023
Last Update Posted : January 24, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Nephrotic Syndrome | Device: renal doppler |
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 60 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 6 Months |
Official Title: | Renal Doppler in Detection of Steroid Resistance in Pediatric Patients With Idiopathic Nephrotic Syndrome |
Actual Study Start Date : | January 28, 2023 |
Actual Primary Completion Date : | July 30, 2023 |
Actual Study Completion Date : | August 30, 2023 |
- Device: renal doppler
Toshiba Aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity
- detection of steroid resistance in pediatric patients with idiopathic nephrotic syndrome [ Time Frame: 6 weeks ]measurement of renal resistive index and detection of steroid sensitivity
- progression of nephrotic syndrome [ Time Frame: six months ]frequent measurement of renal resistive index and using it as prognostic factor
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Pediatric patients with primary nephrotic syndrome aged from 1 to 18 years
Exclusion Criteria:
- - Patients with congenital nephrotic syndrome.
- Patients with secondary causes of nephrotic syndrome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05912673
Egypt | |
Sara Mabrouk Mohamed Elghoul | |
Tanta, Egypt |
Principal Investigator: | Sara Mabrouk Mohamed Elghoul, MD | Tanta University |
Responsible Party: | Sara Mabrouk Elghoul, Tanta, Stadium Street, Tanta University |
ClinicalTrials.gov Identifier: | NCT05912673 |
Other Study ID Numbers: |
36264PR25/1/23 |
First Posted: | June 22, 2023 Key Record Dates |
Last Update Posted: | January 24, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
renal doppler nephrotic syndrome steroid resistance |
Nephrotic Syndrome Nephrosis Syndrome Disease Pathologic Processes Kidney Diseases |
Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases |